Arrowhead Research Corp

Type: Company
Name: Arrowhead Research Corp
First reported 14 hours ago - Updated 14 hours ago - 1 reports

Time To Look For Some Biotech Value

That doesn’t mean that the two targeted sectors will rebound equally. Social media valuations do seem to have more potential problems. Because Facebook (FB) has solved the problem of monetizing popularity in the space the assumption is that the smaller ... [Published Nasdaq - 14 hours ago]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Shares of Arrowhead Research Under Pressure, Down 4.8%

Written on Mon, 07/21/2014 - 11:08amBy Nick RussoOne of today's stocks on the move is Arrowhead Research ( NASDAQ:ARWR ), down 4.8% to $10.80. The Dow is down 0.5% to 17,010 and the S&P is currently down 0.4% to 1,970.Arrowhead Research is in SmarTrend's ... [Published Comtex SmarTrend - Jul 21 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

SEC Filings, Positive Trial Results, Technical Updates, and sNDA Updates - Analyst Notes on Questcor, Exelixis, InterMune, Progenics and Arrowhead

Editor Note: For more information about this release, please scroll to bottomPR NewswireNEW YORK, July 18, 2014NEW YORK , July 18, 2014 /PRNewswire/ --Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: ... [Published Reuters - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Arrowhead Research Corp Short Interest Up 48.1% in June (ARWR)

Arrowhead Research Corp (NASDAQ:ARWR) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totalling 5,486,058 shares, an increase of 48.1% from the June 13th total of 3,704,908 shares, reports. ... [Published American Banking News - Jul 16 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

ARWR Makes Bullish Cross Above Critical Moving Average

In trading on Monday, shares of Arrowhead Research Corp (ARWR) crossed above their 200 day moving average of $12.66, changing hands as high as $12.84 per share. Arrowhead Research Corp shares are currently trading up about 3.2% on the day.. ... [Published Chicago Daily Herald - Jul 14 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

Technical Updates, License Agreements, and Acquisitions - Analyst Notes on Incyte, BioMarin, Arrowhead, Ligand and Techne

/PRNewswire/ --Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Arrowhead Research Corp. (NASDAQ: ARWR), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and ... [Published FinanzNachrichten.de - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Shares of Arrowhead Research Under Pressure, Down 5.2%

Written on Mon, 07/07/2014 - 12:28pmBy James QuinnArrowhead Research ( NASDAQ:ARWR ), a company whose shares are moving quickly, is trading 5.2% lower to $12.50. The S&P is currently trading 0.5% lower to 1,975 and the Dow Jones Industrial Average is ... [Published Comtex SmarTrend - Jul 07 2014]
First reported Jul 02 2014 - Updated Jul 03 2014 - 1 reports

Stock Investors Sell Off Shares of Arrowhead Research, Down 3.0%

One of today's notable stocks in decline is Arrowhead Research (NASDAQ:ARWR), down 3.0% to $13.18. The Dow Jones Industrial Average is now trading fractionally higher to 16,972 and the S&P is trading fractionally higher to 1,974. ... [Published Individual.com - Jul 02 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Arrowhead Research Corporation - Product Pipeline Review - 2014

at 11:36 AM EDT Naperville, IL -- (SBWIRE) -- 06/30/2014 -- Reportstack, provider of premium market research reports announces the addition of Arrowhead Research Corporation - Product Pipeline Review - 2014 market report to its offering Arrowhead Research ... [Published Fat Pitch Financials - Jun 30 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

Biotechnology Equities Movers And Shakers -- Research On ZIOPHARM Oncology, Clovis Oncology, Arrowhead Research, And NPS Pharma

LONDONOn Thursday, June 26, 2014SOURCE Investor-Edge ... [Published TheStreet.com - Jun 27 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 2 reports

Clinical Studies, Trials Results, Appointments, and Technical Updates - Analyst Notes on Ohr, Ariad, Arrowhead, CytRx and Karyopharm Therapeutics

PR NewswireNEW YORK, June 27, 2014NEW YORKToday, Analysts Review released its analysts' notes regarding Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Arrowhead Research Corp. (NASDAQ: ARWR), CytRx Corporation (NASDAQ: ... [Published Digital Journal - Jun 27 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Zacks Reiterates Outperform Rating for Arrowhead Research Corp (ARWR)

Arrowhead Research Corp (NASDAQ:ARWR)Zacks’ analyst wrote, "ARWR is a clinical stage biotech company focused on RNAi targeted therapy using DPC platform technology. We are optimistic about the Company’s lead program ARC-520 for HBV. ARWR presented Phase ... [Published American Banking News - Jun 23 2014]

Quotes

...significant increase in progression-free survival (PFS) for the combination of cobimetinib plus vemurafenib as compared to vemurafenib alone. "These positive top-line results from coBRIM represent an important milestone for melanoma patients and their physicians, and are the first of four anticipated phase 3 pivotal trial read-outs for Exelixis-discovered compounds in 2014" said Michael M Morrissey , Ph D , President and CEO of Exelixis...
...Charles R Kummeth, President and CEO of Bio-Techne, commented, "This acquisition is consistent with our mission to expand our products offering and ensure that our customers are being served in the most complete fashion with the best quality reagents. We are eager to adopt the digital commercial platforms that Novus Biologicals has perfected over the years to accelerate the growth of our overall business." The full analyst notes on Techne are available to download free of charge at:
On Thursday, ZIOPHARM Oncology Inc. "s stock recorded a trading volume of 1.03 million shares, lower than its three months average volume of 1.08 million shares. The stock finished the day at $4.05, down 5.37%, and registered an intraday range of $4.02 and $4.27. ZIOPHARM Oncology Inc." s shares have surged 20.54% in the last one month. However, the stock has declined 17.43% in the previous three months and 6.68% on YTD basis...
...Ohr President and CEO, Dr. Irach B Taraporewala, said, "The data further validate not only the clinical utility of non-invasive topical eye drop therapies for macular and retinal disorders, but also the soundness of our company's drug development science, and our proprietary formulation technologies that enable topical dosing to achieve positive therapeutic effects in back-of-the-eye disorders." The Company stated that it plans to present the full data from this interim analysis in H2 2014, and final clinical trial data is expected in Q1 2015...

More Content

All (101) | News (59) | Reports (0) | Blogs (32) | Audio/Video (0) | Fact Sheets (0) | Press Releases (9)
sort by: Date | Relevance
Time To Look For Some Biotech Value [Published Nasdaq - 14 hours ago]
Shares of Arrowhead Research Under Pressure, Do... [Published Comtex SmarTrend - Jul 21 2014]
SEC Filings, Positive Trial Results, Technical ... [Published Reuters - Jul 18 2014]
SEC Filings, Positive Trial Results, Technical ... [Published Financial Services - Jul 18 2014]
Arrowhead Research Corp Short Interest Up 48.1%... [Published American Banking News - Jul 16 2014]
ARWR Makes Bullish Cross Above Critical Moving ... [Published Chicago Daily Herald - Jul 14 2014]
14 Insanely Important Biotech/Drug Trading Cata... [Published TheStreet.com - Jul 10 2014]
14 Insanely Important Biotech/Drug Trading Cata... [Published The Street Latest - Jul 10 2014]
Arrowhead Issues a Statement on Intellectual Pr... [Published Pharma Letter - Jul 10 2014]
Preliminary Q2 Results Spell Trouble for Gigamo... [Published Value Walk - Jul 09 2014]
Pixelworks Inc. (PXLW) Leads Small-Cap Stars fo... [Published Equities.com - Jul 09 2014]
'Fast Money' Recap: Waiting for the Dust to Settle [Published TheStreet.com - Jul 09 2014]
'Fast Money' Recap: Waiting for the Dust to Settle [Published The Street Latest - Jul 09 2014]
Technical Updates, License Agreements, and Acqu... [Published FinanzNachrichten.de - Jul 08 2014]
Technical Updates, License Agreements, and Acqu... [Published Pettinga Financial Advisors - Jul 08 2014]
Technical Updates, License Agreements, and Acqu... [Published Financial Services - Jul 08 2014]
Shares of Arrowhead Research Under Pressure, Do... [Published Comtex SmarTrend - Jul 07 2014]
Stock Investors Sell Off Shares of Arrowhead Re... [Published Individual.com - Jul 02 2014]
4 Biotech Stocks With Big Money Coming In [Published Benzinga.com - Jun 30 2014]
Arrowhead Research Corporation - Product Pipeli... [Published Fat Pitch Financials - Jun 30 2014]
Video: Friday Sector Laggards: Biotechnology, D... [Published IT Business Net - Jun 27 2014]
Biotechnology Equities Movers And Shakers -- Re... [Published TheStreet.com - Jun 27 2014]
Biotechnology Equities Movers and Shakers -- Re... [Published Yahoo! Finance - Jun 27 2014]
Clinical Studies, Trials Results, Appointments,... [Published Digital Journal - Jun 27 2014]
Clinical Studies, Trials Results, Appointments,... [Published Michigan Live - Jun 27 2014]
Clinical Studies, Trials Results, Appointments,... [Published Financial Services - Jun 27 2014]
Newest Soros Picks a Mixed Bag on Monday [Published Value Walk - Jun 23 2014]
Investing in the Best Canadian Biotech Stocks [Published Equities.com - Jun 23 2014]
Better Buy: Isis Pharmaceuticals vs. Arrowhead ... [Published Motley Fool Discussion Boards - Jun 23 2014]
Zacks Reiterates Outperform Rating for Arrowhea... [Published American Banking News - Jun 23 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Arrowhead Announces New Clinical Candidate ARC-... [Published Business Wire Health News - Jun 19 2014]
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research announces new RNAi candidate ARC-AAT to treat alpha-1 antitrypsin deficiency and holds analyst day to present data ...
Upcoming Conferences, Tentative Meeting Schedul... [Published PR Newswire: Financial Services - Jun 17 2014]
NEW YORK, June 17, 2014 /PRNewswire/ --Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Arrowhead Research Corp. (NASDAQ: ARWR), Novavax, Inc. (NASDAQ: NVAX) and ...
Arrowhead Research Set to Join Russell 3000 Index [Published EON Business - Jun 16 2014]
PASADENA, Calif.--(EON: Enhanced Online News)--Arrowhead Research is set to join he Russell 3000 index when Russell Investments reconstitutes the its U.S. and global indexes on June 27 ...
Arrowhead Research Set to Join Russell 3000 Index [Published Business Wire Professional Services News - Jun 16 2014]
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research is set to join he Russell 3000 index when Russell Investments reconstitutes the its U.S. and global indexes on June 27 ...
Arrowhead Research Set to Join Russell 3000 Index [Published Business Wire Health News - Jun 16 2014]
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research is set to join he Russell 3000 index when Russell Investments reconstitutes the its U.S. and global indexes on June 27 ...
1 2 3 4 5 6 7

Press Releases

sort by: Date | Relevance
SEC Filings, Positive Trial Results, Technical ... [Published Financial Services - Jul 18 2014]
Technical Updates, License Agreements, and Acqu... [Published Financial Services - Jul 08 2014]
Clinical Studies, Trials Results, Appointments,... [Published Financial Services - Jun 27 2014]
Strategic Acquisitions, Clinical Data Presentat... [Published Financial Services - Jun 06 2014]
Top Gainers on the Move -- Research on Arrowhea... [Published Financial Services - Apr 23 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.